GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

NCT00886626 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 medication helps reduce body weight and improve blood sugar control in children who are obese.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 12 people

Who can join Ages 8–19 · all sexes

Timeline Started 2009-05 · est. completion 2011-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00886626 ↗

Description as written by the study sponsor.

The prevalence of severely obese children is on the rise. Behavioral therapies for weight loss are successful in some, but others need more aggressive approaches such as drug therapy. In addition, up to 25% of severely obese children have impaired glucose tolerance (IGT), which places them at significantly elevated risk of developing type 2 diabetes mellitus and cardiovascular disease. Although various drug therapies for weight loss and IGT have been explored in adults, few have been evaluated in children. Recently, a new drug class has emerged that targets deficiencies of GLP-1. One of the main glycemic mechanisms of action of the GLP-1 agonists such as exenatide is to enhance glucose disposal in the postprandial setting and improve glucose tolerance. In addition, exenatide can induce weight loss by decreasing appetite and slowing gastric motility.

Treatments tested

Exenatide also known as Byetta Drug

Exenatide, subcutaneous injection, 10 mcg, twice per day

Main thing measured	Change in Body Mass Index (BMI)
Sponsor	University of Minnesota
Conditions studied	Obesity, Morbid
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00886626 ↗